Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Verweij

Showing results (491-500 of 584) with videos related to

Pageof 59
Sort By:
The EMBO Journal|April 30, 2011
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activationFrederik J Verweij, Monique A J van Eijndhoven, Erik S Hopmans, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedureL J van Warmerdam, G J Creemers, S Rodenhuis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
Frontiers in Pediatrics|December 27, 2021
Ethical Development of Artificial Amniotic Sac and Placenta Technology: A RoadmapE J Verweij, Lien De Proost, Judith O E H van Laar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Trials|April 24, 2015
The Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trialMargaret Nampijja, Emily L Webb, James Kaweesa, et al.
The Journal of Infectious Diseases|February 15, 2013
Asymptomatic plasmodial infection is associated with increased tumor necrosis factor receptor II-expressing regulatory T cells and suppressed type 2 immune responsesLinda J Wammes, Aprilianto E Wiria, Christa G Toenhake, et al.
British Journal of Cancer|July 2, 1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patientsR de Wit, W H Kruit, C H Lamers, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumoursM J A de Jonge, J Verweij, A van der Gaast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-artP Reichardt, J-Y Blay, I Boukovinas, et al.
Pageof 59

Showing results (491-500 of 584) with videos related to

Sort By:
Pageof 59
The EMBO Journal|April 30, 2011
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activationFrederik J Verweij, Monique A J van Eijndhoven, Erik S Hopmans, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedureL J van Warmerdam, G J Creemers, S Rodenhuis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
Frontiers in Pediatrics|December 27, 2021
Ethical Development of Artificial Amniotic Sac and Placenta Technology: A RoadmapE J Verweij, Lien De Proost, Judith O E H van Laar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Trials|April 24, 2015
The Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trialMargaret Nampijja, Emily L Webb, James Kaweesa, et al.
The Journal of Infectious Diseases|February 15, 2013
Asymptomatic plasmodial infection is associated with increased tumor necrosis factor receptor II-expressing regulatory T cells and suppressed type 2 immune responsesLinda J Wammes, Aprilianto E Wiria, Christa G Toenhake, et al.
British Journal of Cancer|July 2, 1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patientsR de Wit, W H Kruit, C H Lamers, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumoursM J A de Jonge, J Verweij, A van der Gaast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2012
Adjuvant therapy in primary GIST: state-of-the-artP Reichardt, J-Y Blay, I Boukovinas, et al.
Pageof 59